Investing.comCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 22:00:38·⟳ 抓取 22:01:44 +1m06s·⚡ 决策 08-31 22:05:50 +4m06s·57.1 天前
康宝莱重申8月5日已给出的2026年三季度及全年指引
本次Investing.com快讯的核心数字与8月5日公司8-K/新闻稿已披露的指引一致，未带来新的业绩预期差或可交易催化。
📄 原文Investing.com↗ 原文
Herbalife reaffirms third quarter and full-year 2026 guidance
Wall Street slips at the open as oil prices surge on sharp U.S.-Iran escalation LOS ANGELES - Herbalife Ltd. (NYSE:HLF)…
不做 Herbalife Ltd.（HLF.US）
不做Herbalife Ltd.（HLF.US）：本次只是重申8月5日已披露的2026年三季度及全年指引，没有新增上修、下修或可量化预期差。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
康宝莱只是重申此前三季度和全年2026年指引，三季度销售、全年销售和调整后EBITDA区间均与8月5日官方披露一致。该消息确认经营轨迹未恶化，但也没有上调、订单、资本回报或其它新增事实；对Herbalife Ltd.（HLF.US）当前股价缺乏可交易的增量预期差，因此不做。
消息传播链
- Herbalife于8月5日提交8-K并披露2026年三季度及全年指引，构成本次数字的原始披露。
- Investing.com报道称公司重申8月5日给出的三季度和全年2026年指引，未披露新增区间变化。
关键理由
- 三季度调整后EBITDA指引1.60亿至1.80亿美元，对比2025年三季度1.63亿美元，只是维持此前区间而非新增上修。
- 全年调整后EBITDA指引6.70亿至6.90亿美元，对比2025年6.576亿美元，增量已在8月5日披露过。
- 8月5日8-K显示全年指引当时已经修订，本次8月31日重申没有改变收入、EBITDA或资本开支假设。
主要风险
- 若市场原本担心公司会下修，重申可能提供边际稳定性，但正文未显示这种预期差足以支撑追涨。
- 美股盘中可交易但实时行情未能通过指定stock_quote取得，且本结论本身不需要下单价格。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-05 · 影响 invalidates
反向证据显示本次所谓利好数字已在8月5日官方披露，削弱做多的新鲜度和预期差。
检索:Herbalife 2026 guidance August 5 2026 SEC 8-K reaffirmed unchanged 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论，决定性因素是本次没有增量信息。
方向:无需用历史先例支持交易方向；本事件本身没有新增事实，方向为中性。
涨幅量级:没有进入幅度校准，因为未形成ENTER候选。
形态:重申既有指引通常需要看是否存在预期差；本次已由原始8月5日披露消解。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 1,997 字
Wall Street slips at the open as oil prices surge on sharp U.S.-Iran escalation
LOS ANGELES - Herbalife Ltd. (NYSE:HLF) reaffirmed its third quarter and full-year 2026 financial guidance on Monday, maintaining the outlook it provided on August 5, 2026.
The health and wellness company continues to expect year-over-year net sales growth for both the third quarter and full year 2026 on a reported and constant currency basis, according to a press release statement. The company also reaffirmed its adjusted EBITDA guidance for both periods.
For the third quarter, Herbalife projects net sales growth of 0.5% to 4.5% on a reported basis and 1.5% to 5.5% on a constant currency basis compared to the prior year. Adjusted EBITDA is expected to range between $160 million and $180 million, with capital expenditures between $15 million and $25 million. In the third quarter of 2025, the company reported net sales of $1,273.7 million and adjusted EBITDA of $163.0 million.
For the full year 2026, the company expects net sales growth of 2.5% to 5.5% on both a reported and constant currency basis. Adjusted EBITDA is projected to range from $670 million to $690 million on a reported basis and $690 million to $710 million on a constant currency basis. Capital expenditures are expected between $50 million and $70 million. Full-year 2025 net sales were $5,037.5 million with adjusted EBITDA of $657.6 million.
"Our outlook for the remainder of the year remains firmly on track," said John DeSimone, Chief Financial Officer. "We remain confident in our ability to deliver a fifth consecutive quarter of year-over-year net sales growth and continued momentum across the remainder of 2026."
The company’s guidance assumptions, including foreign exchange rates based on average daily exchange rates for the first two weeks of July 2026, remain unchanged from those disclosed on August 5, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LOS ANGELES - Herbalife Ltd. (NYSE:HLF) reaffirmed its third quarter and full-year 2026 financial guidance on Monday, maintaining the outlook it provided on August 5, 2026.
The health and wellness company continues to expect year-over-year net sales growth for both the third quarter and full year 2026 on a reported and constant currency basis, according to a press release statement. The company also reaffirmed its adjusted EBITDA guidance for both periods.
For the third quarter, Herbalife projects net sales growth of 0.5% to 4.5% on a reported basis and 1.5% to 5.5% on a constant currency basis compared to the prior year. Adjusted EBITDA is expected to range between $160 million and $180 million, with capital expenditures between $15 million and $25 million. In the third quarter of 2025, the company reported net sales of $1,273.7 million and adjusted EBITDA of $163.0 million.
For the full year 2026, the company expects net sales growth of 2.5% to 5.5% on both a reported and constant currency basis. Adjusted EBITDA is projected to range from $670 million to $690 million on a reported basis and $690 million to $710 million on a constant currency basis. Capital expenditures are expected between $50 million and $70 million. Full-year 2025 net sales were $5,037.5 million with adjusted EBITDA of $657.6 million.
"Our outlook for the remainder of the year remains firmly on track," said John DeSimone, Chief Financial Officer. "We remain confident in our ability to deliver a fifth consecutive quarter of year-over-year net sales growth and continued momentum across the remainder of 2026."
The company’s guidance assumptions, including foreign exchange rates based on average daily exchange rates for the first two weeks of July 2026, remain unchanged from those disclosed on August 5, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。